A phase I study of pexidartinib, a colony-stimulating factor 1 receptor inhibitor, in Asian patients with advanced solid tumors
Open accessThe DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
Summary: Background Pexidartinib, a novel, orally administered small-molecule tyrosine kinase inhibitor, has strong selectivity against colony-stimulating factor 1 receptor. This phase I, nonrandomized, open-label multiple-dose study evaluated pexidartinib safety and efficacy in Asian patients with symptomatic, advanced solid tumors. Materials and Methods Patients received pexidartinib: cohort 1, 600 mg/d; cohort 2, 1000 mg/d for 2 weeks, then 800 mg/d. Primary objectives assessed pexidartinib safety and tolerability, and determined the recommended phase 2 dose; secondary objectives evaluated efficacy and pharmacokinetic profile. Results All 11 patients (6 males, 5 females; median age 64, range 23–82; cohort 1 n = 3; cohort 2 n = 8) experienced at least one treatment-emergent adverse event; 5 experienced at least one grade ≥ 3 adverse event, most commonly (18%) for each of the following: increased aspartate aminotransferase, blood alkaline phosphatase, gamma-glutamyl transferase, and anemia. Recommended phase 2 dose was 1000 mg/d for 2 weeks and 800 mg/d thereafter. Pexidartinib exposure, area under the plasma concentration-time curve from zero to 8 h (AUC 0-8h), and maximum observed plasma concentration (C max) increased on days 1 and 15 with increasing pexidartinib doses, and time at C max (T max) was consistent throughout all doses. Pexidartinib exposure and plasma levels of adiponectin and colony-stimulating factor 1 increased following multiple daily pexidartinib administrations. One patient (13%) with tenosynovial giant cell tumor showed objective tumor response. Conclusions This was the first study to evaluate pexidartinib in Asian patients with advanced solid tumors. Pexidartinib was safe and tolerable in this population at the recommended phase 2 dose previously determined for Western patients (funded by Daiichi Sankyo; clinicaltrials.gov number, NCT02734433).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Tumor-Associated Macrophages and Survival in Classic Hodgkin's Lymphoma
Steidl, C., Lee, T., Shah, S. P., Farinha, P., Han, G., Nayar, T., Delaney, A., Jones, S. J., Iqbal, J., Weisenburger, D. D., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0905680 · Cited by 1,262
Structure-guided blockade of CSF1R kinase in tenosynovial giant-cell tumor
Tap, W. D., Wainberg, Z. A., Anthony, S. P., Ibrahim, P. N., Zhang, C., Healey, J. H., Chmielowski, B., Staddon, A. P., Cohn, A. L., Shapiro, G. I., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1411366 · Cited by 582 · cited 10×
“1) in patients with recurrent or inoperable tenosynovial giant cell tumor (TGCT) [1].”
BackgroundMethodResultInfluentialLamprecht, B., Walter, K., Kreher, S., Kumar, R., Hummel, M., Lenze, D., Köchert, K., Bouhlel, M. A., Richter, J., Soler, E., et al. (2010) · Nature Medicine · doi:10.1038/nm.2129 · Cited by 376
Cited by
Next generation of immune checkpoint inhibitors and beyond
Marin-Acevedo, J. A., Kimbrough, E. O., & Lou, Y. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-021-01056-8 · Cited by 548
Tissue macrophages: origin, heterogenity, biological functions, diseases and therapeutic targets
Guan, F., Wang, R., Yi, Z., Luo, P., Liu, W., Xie, Y., Liu, Z., Xia, Z., Zhang, H., & Cheng, Q. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02124-y · Cited by 371
Tumor microenvironment signaling and therapeutics in cancer progression
Goenka, A., Khan, F., Verma, B., Sinha, P., Dmello, C. C., Jogalekar, M. P., Gangadaran, P., & Ahn, B. (2023) · Cancer Communications · doi:10.1002/cac2.12416 · Cited by 323
Efficient Strategies for Microglia Replacement in the Central Nervous System
Xu, Z., Rao, Y., Huang, Y., Zhou, T., Feng, R., Xiong, S., Yuan, T.-F., Qin, S., Lu, Y., Zhou, X., et al. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.108041 · Cited by 172
The role of tumor-associated macrophages in osteosarcoma progression – therapeutic implications
Huang, Q., Liang, X., Ren, T., Huang, Y., Zhang, H., Yu, Y., Chen, C., Wang, W., Niu, J., Lou, J., et al. (2021) · Cellular Oncology · doi:10.1007/s13402-021-00598-w · Cited by 118
Metadata
- Authors
- Lee, J.-H., Chen, T. W.-W., Hsu, C.-H., Yen, Y.-H., Yang, J. C.-H., Cheng, A.-L., Sasaki, S.-I., Chiu, L., Sugihara, M., Ishizuka, T., Oguma, T., Tajima, N., & Lin, C.-C.
- Venue
- Investigational New Drugs
- Published
- 2019-03-02
- Volume
- 38
- Issue
- 1
- Pages
- 99-110
- ISSN
- 0167-6997 (ISSN-L)
- 1573-0646
- OpenAlex
- W2919838351
- Cited by
- 60
- References
- 3
- FWCI
- 2.22
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A phase I study of pexidartinib, a colony-stimulating factor 1 receptor inhibitor, in Asian patients with advanced solid tumors. https://app.cochat.ai/papers/10.1007/s10637-019-00745-z
- The paper
- Lee, J.-H., Chen, T. W.-W., Hsu, C.-H., Yen, Y.-H., Yang, J. C.-H., Cheng, A.-L., Sasaki, S.-I., Chiu, L., Sugihara, M., Ishizuka, T., Oguma, T., Tajima, N., & Lin, C.-C. (2020). A phase I study of pexidartinib, a colony-stimulating factor 1 receptor inhibitor, in Asian patients with advanced solid tumors. Investigational New Drugs. https://doi.org/10.1007/s10637-019-00745-z
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.